Ana Navas-Acien1, Miranda J Spratlen2, Ahlam Abuawad2, Nancy J LoIacono2, Anne K Bozack2, Mary V Gamble2. 1. Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, 722 W168th Street, New York, NY, 10032, USA. an2737@cumc.columbia.edu. 2. Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, 722 W168th Street, New York, NY, 10032, USA.
Abstract
PURPOSE OF REVIEW: In utero influences, including nutrition and environmental chemicals, may induce long-term metabolic changes and increase diabetes risk in adulthood. This review evaluates the experimental and epidemiological evidence on the association of early-life arsenic exposure on diabetes and diabetes-related outcomes, as well as the influence of maternal nutritional status on arsenic-related metabolic effects. RECENT FINDINGS: Five studies in rodents have evaluated the role of in utero arsenic exposure with diabetes in the offspring. In four of the studies, elevated post-natal fasting glucose was observed when comparing in utero arsenic exposure with no exposure. Rodent offspring exposed to arsenic in utero also showed elevated insulin resistance in the 4 studies evaluating it as well as microRNA changes related to glycemic control in 2 studies. Birth cohorts of arsenic-exposed pregnant mothers in New Hampshire, Mexico, and Taiwan have shown that increased prenatal arsenic exposure is related to altered cord blood gene expression, microRNA, and DNA methylation profiles in diabetes-related pathways. Thus far, no epidemiologic studies have evaluated early-life arsenic exposure with diabetes risk. Supplementation trials have shown B vitamins can reduce blood arsenic levels in highly exposed, undernourished populations. Animal evidence supports that adequate B vitamin status can rescue early-life arsenic-induced diabetes risk, although human data is lacking. Experimental animal studies and human evidence on the association of in utero arsenic exposure with alterations in gene expression pathways related to diabetes in newborns, support the potential role of early-life arsenic exposure in diabetes development, possibly through increased insulin resistance. Given pervasive arsenic exposure and the challenges to eliminate arsenic from the environment, research is needed to evaluate prevention interventions, including the possibility of low-cost, low-risk nutritional interventions that can modify arsenic-related disease risk.
PURPOSE OF REVIEW: In utero influences, including nutrition and environmental chemicals, may induce long-term metabolic changes and increase diabetes risk in adulthood. This review evaluates the experimental and epidemiological evidence on the association of early-life arsenic exposure on diabetes and diabetes-related outcomes, as well as the influence of maternal nutritional status on arsenic-related metabolic effects. RECENT FINDINGS: Five studies in rodents have evaluated the role of in utero arsenic exposure with diabetes in the offspring. In four of the studies, elevated post-natal fasting glucose was observed when comparing in utero arsenic exposure with no exposure. Rodent offspring exposed to arsenic in utero also showed elevated insulin resistance in the 4 studies evaluating it as well as microRNA changes related to glycemic control in 2 studies. Birth cohorts of arsenic-exposed pregnant mothers in New Hampshire, Mexico, and Taiwan have shown that increased prenatal arsenic exposure is related to altered cord blood gene expression, microRNA, and DNA methylation profiles in diabetes-related pathways. Thus far, no epidemiologic studies have evaluated early-life arsenic exposure with diabetes risk. Supplementation trials have shown B vitamins can reduce blood arsenic levels in highly exposed, undernourished populations. Animal evidence supports that adequate B vitamin status can rescue early-life arsenic-induced diabetes risk, although human data is lacking. Experimental animal studies and human evidence on the association of in utero arsenic exposure with alterations in gene expression pathways related to diabetes in newborns, support the potential role of early-life arsenic exposure in diabetes development, possibly through increased insulin resistance. Given pervasive arsenic exposure and the challenges to eliminate arsenic from the environment, research is needed to evaluate prevention interventions, including the possibility of low-cost, low-risk nutritional interventions that can modify arsenic-related disease risk.
Authors: Miranda J Spratlen; Maria Grau-Perez; Jason G Umans; Joseph Yracheta; Lyle G Best; Kevin Francesconi; Walter Goessler; Poojitha Balakrishnan; Shelley A Cole; Mary V Gamble; Barbara V Howard; Ana Navas-Acien Journal: Environ Int Date: 2018-10-12 Impact factor: 9.621
Authors: Julia E Rager; Kathryn A Bailey; Lisa Smeester; Sloane K Miller; Joel S Parker; Jessica E Laine; Zuzana Drobná; Jenna Currier; Christelle Douillet; Andrew F Olshan; Marisela Rubio-Andrade; Miroslav Stýblo; Gonzalo García-Vargas; Rebecca C Fry Journal: Environ Mol Mutagen Date: 2013-12-10 Impact factor: 3.216
Authors: Julia E Heck; Mary V Gamble; Yu Chen; Joseph H Graziano; Vesna Slavkovich; Faruque Parvez; John A Baron; Geoffrey R Howe; Habibul Ahsan Journal: Am J Clin Nutr Date: 2007-05 Impact factor: 7.045
Authors: J Christopher States; Amar V Singh; Thomas B Knudsen; Eric C Rouchka; Ntube O Ngalame; Gavin E Arteel; Yulan Piao; Minoru S H Ko Journal: PLoS One Date: 2012-06-15 Impact factor: 3.240
Authors: Chin-Chi Kuo; Barbara V Howard; Jason G Umans; Matthew O Gribble; Lyle G Best; Kevin A Francesconi; Walter Goessler; Elisa Lee; Eliseo Guallar; Ana Navas-Acien Journal: Diabetes Care Date: 2015-01-12 Impact factor: 19.112
Authors: Maria Tellez-Plaza; Matthew O Gribble; V Saroja Voruganti; Kevin A Francesconi; Walter Goessler; Jason G Umans; Ellen K Silbergeld; Eliseo Guallar; Nora Franceschini; Kari E North; Wen H Kao; Jean W MacCluer; Shelley A Cole; Ana Navas-Acien Journal: Environ Health Perspect Date: 2013-01-15 Impact factor: 9.031